For instance, AR is starting to be recognized as attractive target in triple-negative (ER-/PR-/Her2-) breast cancer (55) and may be a critical target in other human malignancies in which sex differences exist in incidence and mortality, such as bladder cancer and hepatic cell carcinoma (56, 57). This evidence concerns the gene AR and urinary bladder cancer.